|
Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study). |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi |
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst) |
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Genentech/Roche |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Exelixis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Novartis; Pfizer; Pierre Fabre |
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen-Cilag; Novartis; Pfizer; Sanofi |
Research Funding - GlaxoSmithKline (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Roche/Genentech |
|
|
|
Stock and Other Ownership Interests - Roche/Genentech |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
|
|
|
Stock and Other Ownership Interests - Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
|
|
No Relationships to Disclose |